Skip to main content

P53 MUTATIONS ARE INFREQUENT AND DO NOT CORRELATE WITH THE METASTATIC POTENTIAL OF HUMAN-MELANOMA CELLS

Buy Article:

$42.00 + tax (Refund Policy)

Eleven human melanoma cell lines with different metastatic ability (both spontaneous and experimental) in nude mice, were analyzed for p53 mutations. Mutations in the conserved regions of the p53 gene were identified by single-strand conformation polymorphism analysis of exons 5-9 and were verified by direct DNA sequencing of polymerase chain reaction products. A mutation was detected in only one low metastatic melanoma cell line with a C->G transition at codon 278, resulting in a substitution of arginine for proline. Only this cell line reacted immunohistochemically with mouse monoclonal antibody PAb 1801, which is immunoreactive with human p53 protein. Another cell line with low metastatic potential showed loss of heterozygosity for p53 with the remaining allele being normal. No mutations were detected in the highly metastatic melanoma cell lines' We conclude that p53 mutations are infrequent in human melanomas and are not a prerequisite for the acquisition of the metastatic phenotype.

Document Type: Research Article

Affiliations: UNIV TEXAS,MD ANDERSON CANC CTR,DEPT CELL BIOL,BOX 173,1515 HOLCOMBE BLVD,HOUSTON,TX 77030.

Publication date: 01 July 1993

More about this publication?
  • The International Journal of Oncology provides an international forum for the publication of the latest, cutting-edge research in the broad area of oncology and cancer treatment. The journal accepts original high quality works and reviews on all aspects of oncology research including carcinogenesis, metastasis, epidemiology, chemotherapy and viral oncology. Through fair and efficient peer review, the journal is dedicated to publishing top tier research in the field, offering authors rapid publication as well as high standards of copy-editing and production. The International Journal of Oncology is published on a monthly basis in both print and early online.
  • Editorial Board
  • Information for Authors
  • Submit a Paper
  • Subscribe to this Title
  • Information for Advertisers
  • Terms & Conditions
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content